ReviewWorld journal of gastrointestinal oncology2017
Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective.
Review in World journal of gastrointestinal oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model.Molecular cancer therapeutics · 2023Article
- Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study.Cancer reports (Hoboken, N.J.) · 2022Observational
- Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer.Reviews in endocrine & metabolic disorders · 2021Review
- Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors.Frontiers in endocrinology · 2021Review
- Multiple Endocrine Neoplasia Type 1: The Potential Role of microRNAs in the Management of the Syndrome.International journal of molecular sciences · 2020Review
- Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.Nature reviews. Endocrinology · 2020Review
- Article
- Neuroendocrine Neoplasms of the Small Bowel and Pancreas.Neuroendocrinology · 2020Review
- Molecular prognostic factors in small-intestinal neuroendocrine tumours.Endocrine connections · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of rare tumors whose site-specific tumor incidence and clinical behavior vary widely. Genetic alterations associated with familial inherited syndromes have been well defined; however, the genetic profile of sporadic tumors is less clear as their tumorigenesis does not appear to be controlled by classic oncogenes such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.